Health Condition 1: R00-R99- Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
Conditions
Interventions
Intervention1: nil: nil
Sponsors
Duke NUS Program Grant Award
Eligibility
Inclusion criteria
Inclusion criteria: 1)Patients newly started on anti tuberculosis treatment will be included in the study. 2)Each patient will be followed up until the duration of treatment is completed depending on the treatment regime. 3)Once follow up is completed for all recruited patients, EON(Ethambutol optic neuropathy) will be defined by visual acuity assessment to test the inability of the patient to see clearly in dim light post treatment. 4)Patients who develop EON during the study period will be classified as cases and treated patients who did not develop EON will be classified as controls.
Exclusion criteria
Exclusion criteria: Patients with previous optic neuropathy of other causes and retinal pathology causing vision impairment will be excluded
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Biomarker Discovery and Replication - To uncover the genetic susceptibility factors that predisposed treated patients to the development of EON.Timepoint: 1 month, 3 months, 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)To study the clinical profile of patients who develop EON. 2)Biomarker Discovery and Replication - To uncover the genetic susceptibility factors that predisposed treated patients to the development of EON.Timepoint: 1 month, 3 months, 6 months | — |
Countries
India
Contacts
Public ContactDrVirna M Shah
Aravind Eye Hospital
Outcome results
None listed